Probion Blog

  1. The Gut Microbiota and Colorectal Cancer

    The Gut Microbiota and Colorectal Cancer

    It has become increasingly clear that the human gut microbiota contributes to the development of colorectal cancer; the second most common cancer diseases worldwide.1 By modulating several host processes, including inflammation, metabolism, and immune response, the microbiota has the potential to drive cancer development, but also to prevent and reverse this process.

    Specific gut bacteria may drive development of colorectal cancer

    In a recent study, conducted at the Sahlgrenska Academy in collaboration with DuPont Nutrition and Health, we showed that patients with colon cancer had a microbiota enriched for cancer-associated bacteria, including Fusobacterium, compared with individuals without colon cancer.2

    Metagenomic analyses have previously indicated that Fusobacterium spp. are associated with human colorectal cancer but whether the link is indirect or causal has remained unclear. However, in a stu

    Read more »
  2. The Digestive Contract of Friendly Bacteria & Gut Health

    "The Digestive Contract of Friendly Bacteria & Gut Health"

    Lennart Cedgård MD and CEO Wasa Medicals, Halmstad, Sweden


    Probiotics have been defined as a live microbial feed supplement that beneficially influences the health of the host by improving the intestinal microflora.  The use of probiotic bacteria in therapy is not a new invention. Yoghurt, containing probiotic bacteria have for hundreds of years been appreciated for its health bringing properties. Today, research is ongoing throughout the world to clarify the mechanism of probiotics. Intake of probiotic bacteria have many positive effects on health like increasing the digestion and absorption of nutrients, improvement of intestinal lactose digestion, improving the intestinal milieu, regulating the gut motility, stimulating the immune system, prevention of cancer, reduction of catabolic pro

    Read more »
  3. Autoimmune diseases and other health disorders.

    Excessive stimulation due to bacterial dysbiosis and increased intestinal permeability may produce systemic inflammation due to dysfunctional responses of the adaptive immune system. The gut microbiota is involved in mucosal barrier integrity and immune function and can influence on mucosal immunity and systemic inflammation.

    These microbes can produce hormones, neurotransmitters and neurotoxic metabolites that are linked to many different disorders such as rheumatic diseases, multiple sclerosis, celiac disease chronic fatigue syndrome, fibromyalgia and alcoholism.

    In addition to the gut microbiota, bacterial communities of other sites such as the mouth, lung, and skin have been related to autoimmune diseases.

    1. The role of the gut and microbes in the pathogenesis of spondyloarthritis. Asquith M, Elewaut D, Lin P, Rosenbaum JT
    Read more »
  4. Diarrhea and probiotics

    The reasons for getting diarrhea can be many, from various infections, antibiotics use, Inflammatory Bowel Disease (IBD), Irritable Bowel Disease (IBS) or intense endurance exercise. In common for all these conditions are a changed gut microbiota, and all benefit from treatment with probiotics [1]. It is known that a changed microbiota can give bile salt deconjugation changes leading to changes in stool volume and consistency. Other important functions of the gut microbiota is metabolic (salvages calories, production of short-chain fatty acids, amino acids, vitamin K and folic acid); prevention of colonization by pathogens and immunologic functions [2].

    Antibiotics cause diarrhea by several mechanisms, one is that some antibiotics decrease the concentrations of anaerobes, leading to reduced metabolism of carbohydrates and a resultant osmotic diarrhea. Also, during, and in the recover

    Read more »
  5. Intestinal Microflora, Immune System and Probiotics

    The Intestinal Microflora, the Immune System and Probiotics.

    Lennart Cedgård, MD, GM Wasa Medicals, Gothenburg

    Anna Widell BSc in Bioscience, Wasa Medicals, Gothenburg.

    Today there is great scientific interest in the functions of the intestine and the action of intestinal microflora. Research on these issues is ongoing all over the world and one of the main issues is how the intestinal microflora influences the immune system and what effect supplementation of probiotics might have on the immune system.

    The intestinal microflora and the immune system

    There are an enormous number of bacteria colonising our intestines. These bacteria are referred to as " the normal intestinal microflora". The total amount of bacteria colonising our bodies and above all our intestines is ten times higher than the amount of the cells of the body. It follows that 90% of our body

    Read more »
  6. Infrastructure of ProBion Matrix Tablet

    Infrastructure of ProBion Matrix Tablet

    Distribution of microorganisms in tablets

    Wasa medicals produce Probion bifido tablets containing lactic acid bacteria. A new formula for the matrix of the tablet has been tested, which makes it possible to use a lower pressure in the production. It has been shown that with this new technique, the amount of surviving bacteria is very high, when cultivating the bacteria. On a comparison with a reference tablet where a higher pressure had to be used in the production, there was a big difference in the amount of surviving bacteria.


    The goal of this study is to compare the bacteria content in the Probion with the bacteria of the reference tablet. It is of interest to see if different pressures in the production process have an effect on the bacteria. Light microscopy and scanning electron microscopy have been used to

    Read more »
  7. 90% Colon Cancer Microbes Reduced with ProBion Clinica

    GOTHENBURG, Sweden, Sept. 21, 2017

    This study was published in the British Medical Journal (BMJ Open Gastro) July 2017

    ProBion Clinica study demonstrates probiotic intervention response by altering colon-cancer-associated microbiota to non-cancer microbiota.

    ProBion Innovation Sweden AB (PISA), a research biotechnology start-up, announces the results of a clinical trial, registration number NCT03072641, conducted by the Sahlgrenska Academy at University of Gothenburg, in Gothenburg, Sweden, utilizing ProBion Clinica with PISA's proprietary matrix technology on patients with colon cancer. Findings strongly confirm that the colon-cancer-associated microbial signature was modified d

    Read more »